Overview
Istavel D Tablet is a dual-acting oral antidiabetic medication that combines Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. This combination is used for the effective management of type 2 diabetes mellitus in adults. Dapagliflozin reduces glucose reabsorption in the kidneys, promoting glucose excretion through urine, while Sitagliptin enhances incretin hormones to stimulate insulin release and suppress glucagon. Together, they help improve glycemic control without causing significant hypoglycemia or weight gain.





